About RDD Pharma
RDD Pharma is a Healthcare company based in Tel Aviv (Israel) founded in 2008, and was acquired by Innovate Biopharma in October 2019. Developing targeted therapeutics and delivery systems for anorectal and GI disorders. RDD Pharma has raised $16.65 million across 3 funding rounds from investors including PharmaScience, Orbimed and Innovate Biopharma. RDD Pharma offers products and services including Capository, Treatment for Fecal Incontinence, and Treatment for Pruritus Ani. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is RDD Pharma, Ltd.
Company details
RDD Pharma is a clinical stage company focussed on developing drugs and delivery systems for anorectal and gastrointestinal disorders. It is targeting the space between generics and NCEs to develop its pipeline. It is currently initiating a phase 3 study for the treatment of chronic anal fissure with its lead product RDD 1219 along with a sustained release drug delivery device Capository. It also completed phase 2a study of RDD 0315 for fecal incontinence Pruritus Ani. Besides, it has a preclinical program for Radiation Colitis.
- Headquarters Tel Aviv, Israel
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website rddpharma.com
- Social LinkedIn
- Acquired by Innovate Biopharma (Oct 2019)
- Legal Name Rdd Pharma, Ltd
- Total Equity Funding$16.65M (USD)
in 3 rounds
- Latest Funding Round$9.5M (USD), Series B
Nov 2017
- InvestorsPharmaScience
& 3 more
- Acquired byInnovate Biopharma
(Oct 2019)
Products & Services of RDD Pharma
RDD Pharma offers a comprehensive portfolio of products and services, including Capository, Treatment for Fecal Incontinence, and Treatment for Pruritus Ani.
Proprietary system for targeted delivery of treatments to anorectal regions.
Repurposed drug compound for managing fecal incontinence symptoms.
Repurposed medication targeting pruritus ani and related conditions.
Funding Insights of RDD Pharma
RDD Pharma has successfully raised a total of $16.65M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $9.5 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.65M
- Total Rounds 3
- Last Round Series B — $9.5M
- Investors Count 3
All 3 funding rounds of RDD Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2017 | $9.5M | Series B | – | – | |
| Jul 2012 | $7.15M | Series A | – | – | |
| Jun 2009 | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in RDD Pharma
RDD Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include PharmaScience, Orbimed and Innovate Biopharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early-stage real estate startups are funded by Capital Point. | 2000 | capitalpoint.co.il | Tel Aviv, Israel | |
Generic, branded, and over-the-counter pharmaceuticals are manufactured for global markets. | 1983 | pharmascience.com | Montreal, Canada | |
Small molecule drugs and imaging agent for GI disorders | 2012 | innovatebiopharma.com | Raleigh, United States |
Investor details for RDD Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of RDD Pharma
6 people are tracked at RDD Pharma (1 in leadership, 5 in board & advisors).
| Name | Role | Group |
|---|---|---|
Bethany Sensenig | CFO | Leadership |
Mark Sirgo | Chairman | Board & advisors |
Lorin K. Johnson | Director | Board & advisors |
Michael T. Constantino | Director | Board & advisors |
Samantha Ventimiglia | Director | Board & advisors |
Michael Rice | Director | Board & advisors |
Complete people profiles for RDD Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of RDD Pharma
4 dated milestones of RDD Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded RDD Pharma is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $9.5M.
- Exit Acquired by Innovate Biopharma.
Web traffic of RDD Pharma
The website of RDD Pharma (rddpharma.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 44% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rdd Pharma
Complete news archive for RDD Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RDD Pharma
RDD Pharma was founded in 2008 and raised its 1st funding round 1 year after it was founded.
RDD Pharma is headquartered in Tel Aviv, Israel.
RDD Pharma is a funded company, having raised a total of $16.65M across 3 funding rounds to date.
RDD Pharma is a clinical stage company focussed on developing drugs and delivery systems for anorectal and gastrointestinal disorders. It is targeting the space between generics and NCEs to develop its pipeline. It is currently initiating a phase 3 study for the treatment of chronic anal fissure with its lead product RDD 1219 along with a sustained release drug delivery device Capository. It also completed phase 2a study of RDD 0315 for fecal incontinence Pruritus Ani. Besides, it has a preclinical program for Radiation Colitis.
RDD Pharma offers Capository, Treatment for Fecal Incontinence, and Treatment for Pruritus Ani.
RDD Pharma has 4 investors. Key investors include PharmaScience, Orbimed, Innovate Biopharma, and Capital Point.
RDD Pharma operates through Rdd Pharma, Ltd.
Yes. RDD Pharma was acquired by Innovate Biopharma in October 2019.